Trastuzumab was the first FDA-approved anti-HER-2 mAB in 1998, and remains the first-line therapy for early, advanced, and (in combination therapy) also for metastatic, HER-2+ BC (92). This evidence concerns the gene ERBB2 and breast cancer.